journal
MENU ▼
Read by QxMD icon Read
search

New England Journal of Medicine

journal
https://www.readbyqxmd.com/read/30417737/randomized-trial-of-endoscopic-or-open-vein-graft-harvesting-for-coronary-artery-bypass
#1
Marco A Zenati, Deepak L Bhatt, Faisal G Bakaeen, Eileen M Stock, Kousick Biswas, J Michael Gaziano, Rosemary F Kelly, Elaine E Tseng, Jerene Bitondo, Jacquelyn A Quin, G Hossein Almassi, Miguel Haime, Brack Hattler, Ellen DeMatt, Alexandra Scrymgeour, Grant D Huang
BACKGROUND: The saphenous-vein graft is the most common conduit for coronary-artery bypass grafting (CABG). The influence of the vein-graft harvesting technique on long-term clinical outcomes has not been well characterized. METHODS: We randomly assigned patients undergoing CABG at 16 Veterans Affairs cardiac surgery centers to either open or endoscopic vein-graft harvesting. The primary outcome was a composite of major adverse cardiac events, including death from any cause, nonfatal myocardial infarction, and repeat revascularization...
November 11, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/30415601/angiotensin-neprilysin-inhibition-in-acute-decompensated-heart-failure
#2
Eric J Velazquez, David A Morrow, Adam D DeVore, Carol I Duffy, Andrew P Ambrosy, Kevin McCague, Ricardo Rocha, Eugene Braunwald
BACKGROUND: Acute decompensated heart failure accounts for more than 1 million hospitalizations in the United States annually. Whether the initiation of sacubitril-valsartan therapy is safe and effective among patients who are hospitalized for acute decompensated heart failure is unknown. METHODS: We enrolled patients with heart failure with reduced ejection fraction who were hospitalized for acute decompensated heart failure at 129 sites in the United States. After hemodynamic stabilization, patients were randomly assigned to receive sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily) or enalapril (target dose, 10 mg twice daily)...
November 11, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/30415637/marine-n-3-fatty-acids-and-prevention-of-cardiovascular-disease-and-cancer
#3
JoAnn E Manson, Nancy R Cook, I-Min Lee, William Christen, Shari S Bassuk, Samia Mora, Heike Gibson, Christine M Albert, David Gordon, Trisha Copeland, Denise D'Agostino, Georgina Friedenberg, Claire Ridge, Vadim Bubes, Edward L Giovannucci, Walter C Willett, Julie E Buring
BACKGROUND: Higher intake of marine n-3 (also called omega-3) fatty acids has been associated with reduced risks of cardiovascular disease and cancer in several observational studies. Whether supplementation with n-3 fatty acids has such effects in general populations at usual risk for these end points is unclear. METHODS: We conducted a randomized, placebo-controlled trial, with a two-by-two factorial design, of vitamin D3 (at a dose of 2000 IU per day) and marine n-3 fatty acids (at a dose of 1 g per day) in the primary prevention of cardiovascular disease and cancer among men 50 years of age or older and women 55 years of age or older in the United States...
November 10, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/30415629/vitamin-d-supplements-and-prevention-of-cancer-and-cardiovascular-disease
#4
JoAnn E Manson, Nancy R Cook, I-Min Lee, William Christen, Shari S Bassuk, Samia Mora, Heike Gibson, David Gordon, Trisha Copeland, Denise D'Agostino, Georgina Friedenberg, Claire Ridge, Vadim Bubes, Edward L Giovannucci, Walter C Willett, Julie E Buring
BACKGROUND: It is unclear whether supplementation with vitamin D reduces the risk of cancer or cardiovascular disease, and data from randomized trials are limited. METHODS: We conducted a nationwide, randomized, placebo-controlled trial, with a two-by-two factorial design, of vitamin D3 (cholecalciferol) at a dose of 2000 IU per day and marine n-3 (also called omega-3) fatty acids at a dose of 1 g per day for the prevention of cancer and cardiovascular disease among men 50 years of age or older and women 55 years of age or older in the United States...
November 10, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/30415628/cardiovascular-risk-reduction-with-icosapent-ethyl-for-hypertriglyceridemia
#5
Deepak L Bhatt, P Gabriel Steg, Michael Miller, Eliot A Brinton, Terry A Jacobson, Steven B Ketchum, Ralph T Doyle, Rebecca A Juliano, Lixia Jiao, Craig Granowitz, Jean-Claude Tardif, Christie M Ballantyne
BACKGROUND: Patients with elevated triglyceride levels are at increased risk for ischemic events. Icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowers triglyceride levels, but data are needed to determine its effects on ischemic events. METHODS: We performed a multicenter, randomized, double-blind, placebo-controlled trial involving patients with established cardiovascular disease or with diabetes and other risk factors, who had been receiving statin therapy and who had a fasting triglyceride level of 135 to 499 mg per deciliter (1...
November 10, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/30415610/low-dose-methotrexate-for-the-prevention-of-atherosclerotic-events
#6
Paul M Ridker, Brendan M Everett, Aruna Pradhan, Jean G MacFadyen, Daniel H Solomon, Elaine Zaharris, Virak Mam, Ahmed Hasan, Yves Rosenberg, Erin Iturriaga, Milan Gupta, Michelle Tsigoulis, Subodh Verma, Michael Clearfield, Peter Libby, Samuel Z Goldhaber, Roger Seagle, Cyril Ofori, Mohammad Saklayen, Samuel Butman, Narendra Singh, Michel Le May, Olivier Bertrand, James Johnston, Nina P Paynter, Robert J Glynn
BACKGROUND: Inflammation is causally related to atherothrombosis. Treatment with canakinumab, a monoclonal antibody that inhibits inflammation by neutralizing interleukin-1β, resulted in a lower rate of cardiovascular events than placebo in a previous randomized trial. We sought to determine whether an alternative approach to inflammation inhibition with low-dose methotrexate might provide similar benefit. METHODS: We conducted a randomized, double-blind trial of low-dose methotrexate (at a target dose of 15 to 20 mg weekly) or matching placebo in 4786 patients with previous myocardial infarction or multivessel coronary disease who additionally had either type 2 diabetes or the metabolic syndrome...
November 10, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/30415602/dapagliflozin-and-cardiovascular-outcomes-in-type-2-diabetes
#7
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John P H Wilding, Christian T Ruff, Ingrid A M Gause-Nilsson, Martin Fredriksson, Peter A Johansson, Anna-Maria Langkilde, Marc S Sabatine
BACKGROUND: The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined. METHODS: We randomly assigned patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease to receive either dapagliflozin or placebo. The primary safety outcome was a composite of major adverse cardiovascular events (MACE), defined as cardiovascular death, myocardial infarction, or ischemic stroke...
November 10, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/30415594/vital-signs-for-dietary-supplementation-to-prevent-cancer-and-heart-disease
#8
John F Keaney, Clifford J Rosen
No abstract text is available yet for this article.
November 10, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/30403574/alirocumab-and-cardiovascular-outcomes-after-acute-coronary-syndrome
#9
Gregory G Schwartz, P Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Jay M Edelberg, Shaun G Goodman, Corinne Hanotin, Robert A Harrington, J Wouter Jukema, Guillaume Lecorps, Kenneth W Mahaffey, Angèle Moryusef, Robert Pordy, Kirby Quintero, Matthew T Roe, William J Sasiela, Jean-François Tamby, Pierluigi Tricoci, Harvey D White, Andreas M Zeiher
BACKGROUND: Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high-intensity statin therapy. METHODS: We conducted a multicenter, randomized, double-blind, placebo-controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low-density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1...
November 7, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/30403541/politics-and-pandemics
#10
Ron Klain
No abstract text is available yet for this article.
November 7, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/30387697/randomized-trial-of-platelet-transfusion-thresholds-in-neonates
#11
Anna Curley, Simon J Stanworth, Karen Willoughby, Susanna F Fustolo-Gunnink, Vidheya Venkatesh, Cara Hudson, Alison Deary, Renate Hodge, Valerie Hopkins, Beatriz Lopez Santamaria, Ana Mora, Charlotte Llewelyn, Angela D'Amore, Rizwan Khan, Wes Onland, Enrico Lopriore, Karin Fijnvandraat, Helen New, Paul Clarke, Timothy Watts
BACKGROUND: Platelet transfusions are commonly used to prevent bleeding in preterm infants with thrombocytopenia. Data are lacking to provide guidance regarding thresholds for prophylactic platelet transfusions in preterm neonates with severe thrombocytopenia. METHODS: In this multicenter trial, we randomly assigned infants born at less than 34 weeks of gestation in whom severe thrombocytopenia developed to receive a platelet transfusion at platelet-count thresholds of 50,000 per cubic millimeter (high-threshold group) or 25,000 per cubic millimeter (low-threshold group)...
November 2, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/30380365/minimally-invasive-versus-abdominal-radical-hysterectomy-for-cervical-cancer
#12
Pedro T Ramirez, Michael Frumovitz, Rene Pareja, Aldo Lopez, Marcelo Vieira, Reitan Ribeiro, Alessandro Buda, Xiaojian Yan, Yao Shuzhong, Naven Chetty, David Isla, Mariano Tamura, Tao Zhu, Kristy P Robledo, Val Gebski, Rebecca Asher, Vanessa Behan, James L Nicklin, Robert L Coleman, Andreas Obermair
BACKGROUND: There are limited data from retrospective studies regarding whether survival outcomes after laparoscopic or robot-assisted radical hysterectomy (minimally invasive surgery) are equivalent to those after open abdominal radical hysterectomy (open surgery) among women with early-stage cervical cancer. METHODS: In this trial involving patients with stage IA1 (lymphovascular invasion), IA2, or IB1 cervical cancer and a histologic subtype of squamous-cell carcinoma, adenocarcinoma, or adenosquamous carcinoma, we randomly assigned patients to undergo minimally invasive surgery or open surgery...
October 31, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/30380364/immune-escape-of-relapsed-aml-cells-after-allogeneic-transplantation
#13
Matthew J Christopher, Allegra A Petti, Michael P Rettig, Christopher A Miller, Ezhilarasi Chendamarai, Eric J Duncavage, Jeffery M Klco, Nicole M Helton, Michelle O'Laughlin, Catrina C Fronick, Robert S Fulton, Richard K Wilson, Lukas D Wartman, John S Welch, Sharon E Heath, Jack D Baty, Jacqueline E Payton, Timothy A Graubert, Daniel C Link, Matthew J Walter, Peter Westervelt, Timothy J Ley, John F DiPersio
BACKGROUND: As consolidation therapy for acute myeloid leukemia (AML), allogeneic hematopoietic stem-cell transplantation provides a benefit in part by means of an immune-mediated graft-versus-leukemia effect. We hypothesized that the immune-mediated selective pressure imposed by allogeneic transplantation may cause distinct patterns of tumor evolution in relapsed disease. METHODS: We performed enhanced exome sequencing on paired samples obtained at initial presentation with AML and at relapse from 15 patients who had a relapse after hematopoietic stem-cell transplantation (with transplants from an HLA-matched sibling, HLA-matched unrelated donor, or HLA-mismatched unrelated donor) and from 20 patients who had a relapse after chemotherapy...
October 31, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/30379613/survival-after-minimally-invasive-radical-hysterectomy-for-early-stage-cervical-cancer
#14
Alexander Melamed, Daniel J Margul, Ling Chen, Nancy L Keating, Marcela G Del Carmen, Junhua Yang, Brandon-Luke L Seagle, Amy Alexander, Emma L Barber, Laurel W Rice, Jason D Wright, Masha Kocherginsky, Shohreh Shahabi, J Alejandro Rauh-Hain
BACKGROUND: Minimally invasive surgery was adopted as an alternative to laparotomy (open surgery) for radical hysterectomy in patients with early-stage cervical cancer before high-quality evidence regarding its effect on survival was available. We sought to determine the effect of minimally invasive surgery on all-cause mortality among women undergoing radical hysterectomy for cervical cancer. METHODS: We performed a cohort study involving women who underwent radical hysterectomy for stage IA2 or IB1 cervical cancer during the 2010-2013 period at Commission on Cancer-accredited hospitals in the United States...
October 31, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/30379600/surgery-in-cervical-cancer
#15
Amanda N Fader
No abstract text is available yet for this article.
October 31, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/30365356/intravenous-iron-in-patients-undergoing-maintenance-hemodialysis
#16
Iain C Macdougall, Claire White, Stefan D Anker, Sunil Bhandari, Kenneth Farrington, Philip A Kalra, John J V McMurray, Heather Murray, Charles R V Tomson, David C Wheeler, Christopher G Winearls, Ian Ford
BACKGROUND: Intravenous iron is a standard treatment for patients undergoing hemodialysis, but comparative data regarding clinically effective regimens are limited. METHODS: In a multicenter, open-label trial with blinded end-point evaluation, we randomly assigned adults undergoing maintenance hemodialysis to receive either high-dose iron sucrose, administered intravenously in a proactive fashion (400 mg monthly, unless the ferritin concentration was >700 μg per liter or the transferrin saturation was ≥40%), or low-dose iron sucrose, administered intravenously in a reactive fashion (0 to 400 mg monthly, with a ferritin concentration of <200 μg per liter or a transferrin saturation of <20% being a trigger for iron administration)...
October 26, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/30354950/pantoprazole-in-patients-at-risk-for-gastrointestinal-bleeding-in-the-icu
#17
Mette Krag, Søren Marker, Anders Perner, Jørn Wetterslev, Matt P Wise, Joerg C Schefold, Frederik Keus, Anne B Guttormsen, Stepani Bendel, Mark Borthwick, Theis Lange, Bodil S Rasmussen, Martin Siegemund, Helle Bundgaard, Thomas Elkmann, Jacob V Jensen, Rune D Nielsen, Lisbeth Liboriussen, Morten H Bestle, Jeanie M Elkjær, Dorte F Palmqvist, Minna Bäcklund, Jon H Laake, Per M Bådstøløkken, Juha Grönlund, Olena Breum, Akil Walli, Robert Winding, Susanne Iversen, Inge-Lise Jarnvig, Jonathan O White, Björn Brand, Martin B Madsen, Lars Quist, Klaus J Thornberg, Anders Møller, Jørgen Wiis, Anders Granholm, Carl T Anthon, Tine S Meyhoff, Peter B Hjortrup, Søren R Aagaard, Jo B Andreasen, Christina A Sørensen, Pernille Haure, Jacob Hauge, Alexa Hollinger, Jonas Scheuzger, Daniel Tuchscherer, Thierry Vuilliomenet, Jukka Takala, Stephan M Jakob, Marianne L Vang, Kim B Pælestik, Karen L D Andersen, Iwan C C van der Horst, Willem Dieperink, Jesper Fjølner, Cilia K W Kjer, Christine Sølling, Christoffer G Sølling, Johanna Karttunen, Matt P G Morgan, Brit Sjøbø, Janus Engstrøm, Birgit Agerholm-Larsen, Morten H Møller
BACKGROUND: Prophylaxis for gastrointestinal stress ulceration is frequently given to patients in the intensive care unit (ICU), but its risks and benefits are unclear. METHODS: In this European, multicenter, parallel-group, blinded trial, we randomly assigned adults who had been admitted to the ICU for an acute condition (i.e., an unplanned admission) and who were at risk for gastrointestinal bleeding to receive 40 mg of intravenous pantoprazole (a proton-pump inhibitor) or placebo daily during the ICU stay...
October 24, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/30354949/proton-pump-inhibitor-prophylaxis-in-the-icu-benefits-worth-the-risks
#18
Alan Barkun, Marc Bardou
No abstract text is available yet for this article.
October 24, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/30346242/haloperidol-and-ziprasidone-for-treatment-of-delirium-in-critical-illness
#19
Timothy D Girard, Matthew C Exline, Shannon S Carson, Catherine L Hough, Peter Rock, Michelle N Gong, Ivor S Douglas, Atul Malhotra, Robert L Owens, Daniel J Feinstein, Babar Khan, Margaret A Pisani, Robert C Hyzy, Gregory A Schmidt, William D Schweickert, R Duncan Hite, David L Bowton, Andrew L Masica, Jennifer L Thompson, Rameela Chandrasekhar, Brenda T Pun, Cayce Strength, Leanne M Boehm, James C Jackson, Pratik P Pandharipande, Nathan E Brummel, Christopher G Hughes, Mayur B Patel, Joanna L Stollings, Gordon R Bernard, Robert S Dittus, E Wesley Ely
BACKGROUND: There are conflicting data on the effects of antipsychotic medications on delirium in patients in the intensive care unit (ICU). METHODS: In a randomized, double-blind, placebo-controlled trial, we assigned patients with acute respiratory failure or shock and hypoactive or hyperactive delirium to receive intravenous boluses of haloperidol (maximum dose, 20 mg daily), ziprasidone (maximum dose, 40 mg daily), or placebo. The volume and dose of a trial drug or placebo was halved or doubled at 12-hour intervals on the basis of the presence or absence of delirium, as detected with the use of the Confusion Assessment Method for the ICU, and of side effects of the intervention...
October 22, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/30346241/dopamine-antagonists-in-icu-delirium
#20
Thomas P Bleck
No abstract text is available yet for this article.
October 22, 2018: New England Journal of Medicine
journal
journal
20199
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"